|
Market Cap | 4.12M | EPS (ttm) | -42.75 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 62.30% |
P/S | 2.09 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 94.28% |
Dividend | - | Sales Q/Q | -28.34% |
Insider Own | - | Inst Own | 15.11% |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | 1.00 | Target Price | 32.00 |
Avg Volume | 63.36K | 52W Range | 1.92 - 398.40 |
|
|
|
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mehra Raj | See Remarks | Dec 01 '23 | Buy | 1.32 | 75,757 | 99,999 | 185,142 | Dec 01 04:16 PM | Golembiewski Michael Joseph | Chief Financial Officer | Nov 30 '23 | Buy | 1.21 | 83,000 | 100,222 | 86,450 | Dec 01 04:16 PM |
|
|
|
|
Market Cap | 10.98M | EPS (ttm) | -102.71 |
P/E | - | EPS this Y | 82.97% |
Forward P/E | - | EPS next Y | 23.39% |
PEG | - | EPS past 5Y | -49.91% |
P/S | 0.20 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 85.43% |
Dividend | - | Sales Q/Q | -70.54% |
Insider Own | 0.00% | Inst Own | 6.43% |
Insider Trans | - | Inst Trans | - |
Short Float | 1.29% | Earnings | May 15/b |
Analyst Recom | 2.00 | Target Price | 53.28 |
Avg Volume | 1.53M | 52W Range | 1.45 - 170.40 |
|
|
|
22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Arno Andrew | Director | Jan 05 '24 | Buy | 0.17 | 100,000 | 17,490 | 100,000 | Jan 08 08:04 PM | FIRESTONE LAWRENCE | Chief Executive Officer | Jan 04 '24 | Buy | 0.17 | 100,000 | 17,360 | 100,000 | Jan 05 04:32 PM |
|
|
|
|
Market Cap | 29.10M | EPS (ttm) | -4.21 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 23.85 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -44077.42% |
Dividend | - | Sales Q/Q | - |
Insider Own | 37.49% | Inst Own | 5.53% |
Insider Trans | 0.00% | Inst Trans | 6.72% |
Short Float | 2.44% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.17M | 52W Range | 0.90 - 18.50 |
|
|
|
Zapata Computing Holdings, Inc. operates as a generative AI company. It provides data science and engineering techniques for solutions on an industrial scale. The company was founded by Christopher Savoie, Alan Aspuru-Guzik, Yudong Cao, Jonathan Olson, Peter Johnson, and Jonathan Romero-Fontalvo in 2017 and is headquartered in Boston, MA. |
|
| |
|
Market Cap | 3.36M | EPS (ttm) | -27.34 |
P/E | - | EPS this Y | 71.22% |
Forward P/E | - | EPS next Y | 17.36% |
PEG | - | EPS past 5Y | 34.89% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 63.17% |
Dividend | - | Sales Q/Q | - |
Insider Own | 0.11% | Inst Own | 23.89% |
Insider Trans | 0.00% | Inst Trans | 99.87% |
Short Float | 2.84% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 20.00 |
Avg Volume | 1.47M | 52W Range | 2.08 - 44.80 |
|
|
|
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX. |
|
|
|
Market Cap | 10.31M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -32.60% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -13.12% |
Dividend | - | Sales Q/Q | -80.94% |
Insider Own | 57.02% | Inst Own | 8.96% |
Insider Trans | 0.00% | Inst Trans | -0.69% |
Short Float | 0.33% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 1.50 |
Avg Volume | 146.82K | 52W Range | 0.36 - 1.98 |
|
|
|
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
|
| |
|
Market Cap | 15.34M | EPS (ttm) | -2.44 |
P/E | - | EPS this Y | 37.33% |
Forward P/E | - | EPS next Y | 40.73% |
PEG | - | EPS past 5Y | -103.84% |
P/S | 0.22 | EPS next 5Y | - |
P/B | 0.06 | EPS Q/Q | -355.70% |
Dividend | - | Sales Q/Q | -87.19% |
Insider Own | 29.58% | Inst Own | 37.62% |
Insider Trans | 0.00% | Inst Trans | 3.20% |
Short Float | 0.56% | Earnings | May 13/b |
Analyst Recom | 3.00 | Target Price | 0.75 |
Avg Volume | 795.27K | 52W Range | 0.09 - 0.89 |
|
|
|
Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA. |
|
|
|
Market Cap | 1.91M | EPS (ttm) | -47.17 |
P/E | - | EPS this Y | 63.72% |
Forward P/E | - | EPS next Y | 70.43% |
PEG | - | EPS past 5Y | 32.73% |
P/S | 0.13 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 69.11% |
Dividend | - | Sales Q/Q | 27.58% |
Insider Own | 12.25% | Inst Own | 1.36% |
Insider Trans | -30.20% | Inst Trans | - |
Short Float | 22.72% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 12.00 |
Avg Volume | 907.10K | 52W Range | 3.61 - 89.60 |
|
|
|
Edible Garden AG, Inc. is a controlled environment agriculture (CEA) farming company, which engages in the usage of traditional agricultural growing techniques together with technology to grow organic food. Its products include lettuces, potted herbs, and cut herbs. The company was founded by James E. Kras and Michael C. James on March 28, 2020 and is headquartered in Belvidere, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
UBS Group AG | 10% Owner | Apr 25 '24 | Buy | 6.07 | 1,005 | 6,105 | 35,077 | May 03 12:04 PM | UBS Group AG | 10% Owner | Apr 25 '24 | Sale | 5.43 | 30,056 | 163,307 | 5,025 | May 03 12:04 PM | UBS Group AG | 10% Owner | Apr 24 '24 | Sale | 6.30 | 106 | 668 | 34,076 | May 03 12:04 PM | DonAroma Pamela | Director | Jun 02 '23 | Buy | 1.51 | 1,000 | 1,510 | 1,000 | Jun 06 04:30 PM |
|
|
| |
|
Market Cap | 40.77M | EPS (ttm) | -2.09 |
P/E | - | EPS this Y | 12.50% |
Forward P/E | - | EPS next Y | -28.57% |
PEG | - | EPS past 5Y | - |
P/S | 0.05 | EPS next 5Y | 15.30% |
P/B | 0.25 | EPS Q/Q | 67.85% |
Dividend | - | Sales Q/Q | -20.67% |
Insider Own | 34.35% | Inst Own | 32.42% |
Insider Trans | 0.00% | Inst Trans | -1.65% |
Short Float | 1.22% | Earnings | May 14/b |
Analyst Recom | 4.00 | Target Price | 2.00 |
Avg Volume | 248.29K | 52W Range | 0.81 - 3.71 |
|
|
|
The Container Store Group, Inc. is a holding company, which engages in the retail of storage and organization products and solutions. It operates through The Container Store and Elfa segments. The Container Store segment focuses on retail stores, website and call centers, as well as the installation and organizational services business. The Elfa segment includes the design and manufacture of component-based shelving and drawer systems and made-to-measure sliding doors. The company was founded in 1978 and is headquartered in Coppell, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Malhotra Satish | CEO & PRESIDENT | Nov 13 '23 | Buy | 1.82 | 16,715 | 30,359 | 754,653 | Nov 15 07:26 PM | Malhotra Satish | CEO & PRESIDENT | Aug 31 '23 | Buy | 2.44 | 12,417 | 30,307 | 737,938 | Sep 01 05:49 PM | Jordan Robert E | Director | Aug 30 '23 | Buy | 2.35 | 30,000 | 70,506 | 224,059 | Sep 01 04:59 PM | Saha Dhritiman | CHIEF OPERATING OFFICER | Aug 08 '23 | Buy | 2.54 | 5,000 | 12,700 | 175,665 | Aug 09 08:23 PM | MILLER JEFFREY A | CHIEF FINANCIAL OFFICER | Aug 04 '23 | Buy | 2.60 | 3,860 | 10,023 | 210,234 | Aug 04 05:16 PM |
|
|
|
|
Market Cap | 9.30B | EPS (ttm) | -1.32 |
P/E | - | EPS this Y | 0.33% |
Forward P/E | - | EPS next Y | 98.88% |
PEG | - | EPS past 5Y | 4.59% |
P/S | 3.67 | EPS next 5Y | - |
P/B | 2.96 | EPS Q/Q | -45.59% |
Dividend | - | Sales Q/Q | 5.82% |
Insider Own | 1.04% | Inst Own | 89.57% |
Insider Trans | -5.35% | Inst Trans | -1.72% |
Short Float | 4.86% | Earnings | May 08/a |
Analyst Recom | 1.33 | Target Price | 86.61 |
Avg Volume | 2.78M | 52W Range | 51.91 - 100.77 |
|
|
|
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Conroy Kevin T | President and CEO | May 01 '24 | Sale | 60.15 | 1,155 | 69,473 | 1,156,191 | May 02 07:00 PM | Cunningham Everett | Chief Commercial Officer | May 01 '24 | Sale | 60.15 | 136 | 8,180 | 47,042 | May 02 07:00 PM | Elliott Jeffrey Thomas | Chief Financial Officer | May 01 '24 | Sale | 60.15 | 136 | 8,180 | 11,795 | May 02 07:00 PM | Baranick Brian | EVP, GM., Precision Oncology | May 01 '24 | Sale | 60.15 | 110 | 6,616 | 13,279 | May 02 07:00 PM | Condella Sarah | EVP, Human Resources | May 01 '24 | Sale | 60.15 | 102 | 6,135 | 72,611 | May 02 07:00 PM |
|
|
|
|
Market Cap | 3.74M | EPS (ttm) | -12.96 |
P/E | - | EPS this Y | 62.43% |
Forward P/E | - | EPS next Y | 44.97% |
PEG | - | EPS past 5Y | 63.34% |
P/S | 5.59 | EPS next 5Y | - |
P/B | 0.66 | EPS Q/Q | 30.36% |
Dividend | - | Sales Q/Q | 21.62% |
Insider Own | 4.61% | Inst Own | 3.02% |
Insider Trans | 8.37% | Inst Trans | - |
Short Float | 2.66% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 4.00 |
Avg Volume | 541.45K | 52W Range | 1.49 - 14.44 |
|
|
|
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ANDREEFF DANE | President and CEO | Dec 14 '23 | Buy | 8.10 | 5,000 | 40,475 | 16,512 | Dec 15 07:00 AM | ANDREEFF DANE | President and CEO | Dec 01 '23 | Buy | 6.45 | 2,006 | 12,935 | 13,685 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Nov 30 '23 | Buy | 6.37 | 2,000 | 12,741 | 12,551 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Aug 30 '23 | Buy | 7.64 | 5,000 | 38,212 | 11,420 | Aug 30 08:42 PM | ANDREEFF DANE | President and CEO | Aug 28 '23 | Buy | 6.37 | 5,078 | 32,339 | 8,774 | Aug 30 08:42 PM |
|
|
|